Deutsche Bank Initiates Coverage On Henry Schein(HSIC). In a research note issued to the investors, the brokerage major Announces the price-target to $174 per share. The shares have been rated Hold. The rating by the stock financial advisor at Deutsche Bank was issued on Mar 15, 2017 in a research report to their Investors and Clients.
In a different note, On Jan 3, 2017, Baird said it Upgrades its rating on Henry Schein. The shares have been rated ‘Outperform’ by the firm.
Henry Schein (HSIC) made into the market gainers list on Fridays trading session with the shares advancing 0.05% or 0.08 points. Due to strong positive momentum, the stock ended at $171.25, which is also near the day’s high of $172. The stock began the session at $171.64 and the volume stood at 9,09,124 shares. The 52-week high of the shares is $183 and the 52 week low is $146.23. The company has a current market capitalization of $13,562 M and it has 7,91,96,697 shares in outstanding.
Henry Schein(HSIC) last announced its earnings results on Feb 21, 2017 for Fiscal Year 2016 and Q4.Company reported revenue of $3.121B. Analysts had an estimated revenue of $3.080B. Earnings per share were $1.88. Analysts had estimated an EPS of $1.85.
Several Insider Transactions has been reported to the SEC. On Mar 9, 2017, Philip A Laskawy (director) sold 1,103 shares at $171.51 per share price.Also, On Mar 9, 2017, James A. Harding (SVP, Chief Technology Officer) sold 10,552 shares at $171.60 per share price.On Mar 8, 2017, James P Breslawski (Pres., HSI & CEO Global Dental) sold 8,486 shares at $170.35 per share price, according to the Form-4 filing with the securities and exchange commission.
Henry Schein Inc. provides health care products and services to office-based dental animal health and medical practitioners. The Company operates its business through two segments: health care distribution and technology and value-added services. The health care distribution segment distributes consumable products laboratory products equipment repair services branded and generic pharmaceuticals vaccines surgical products diagnostic tests infection-control products and vitamins among others. The Company’s global technology and value-added services segment provides software technology and other value-added services to health care practitioners. Its offerings include practice management software systems for dental and medical practitioners and animal health clinics. Its value-added practice solutions include financial services on a non-recourse basis e-services practice technology network and hardware services as well as continuing education services for practitioners.